Apogee Therapeutics is a clinical-stage biotech developing extended half-life monoclonal antibodies (mAbs) for inflammatory and immunology (I&I) conditions, with an initial focus on atopic dermatitis (AD), asthma, eosinophilic esophagitis, and COPD. Apogee has no approved products and generates no revenue. The company's core differentiation is antibody engineering: standard mAbs used in I&I (like Dupixent) require biweekly or monthly injections, while Apogee engineers its antibodies with half-life extension technologies that support dosing every 3–6 months, which Apogee argues improves patient adherence. Apogee's lead asset, zumilokibart, is an anti-IL-13 mAb in Phase 2 for AD, with a potential Phase 3 start in H2 2026 and commercial launch no earlier than 2029. The pipeline also includes APG279, a combination of zumilokibart and an anti-OX40L mAb designed to deliver broad I&I coverage in AD; APG273, a combination targeting IL-13 and TSLP for asthma and COPD; and APG808, a standalone anti-IL-4Rα mAb (the same target as Dupixent). Apogee sources antibody candidates through a partnership with Paragon and outsources manufacturing to CDMOs. The company funds itself through equity raises and intends to commercialize products directly if approved, while owing Paragon royalties and milestone payments on future sales.